[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"coronary-artery-bypass-grafting-cabg\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:coronary-artery-bypass-grafting-cabg":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,60,89,114],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":39,"overallStatus":47,"whyStopped":4,"lastUpdateSubmitDate":48,"lastUpdatePostDateStruct":49,"startDateStruct":52,"completionDateStruct":54,"leadSponsor":56,"locationsCount":59},"100537589","phase-2-intravenous-fish-oil-based-lipid-emulsion-to-enhance-recovery-in-high-risk-cardiac-surgery-patients-100537589",false,"NCT06279793","Intravenous Fish Oil Based Lipid Emulsion to Enhance Recovery in High-Risk Cardiac Surgery Patients","Intravenous Fish Oil Based Lipid Emulsion to Enhance Recovery in High-Risk Cardiac Surgery Patients: a Phase II Multicenter Trial - A Randomized, Placebo-controlled Trial -","MODIFY CSX","Inclusion Criteria:\n\n1. Written informed consent prior to study participation\n2. Adult patients (≥ 18 years)\n3. Patients scheduled to undergo elective cardiac surgery with the use of CPB, who are defined as high risk based on having (i) one of the following surgical procedures: valvular heart surgery only, CABG, combined valve and CABG, multiple valve surgeries, combined cardiac procedures, aortic surgical procedures (aortic arch and\u002For descending aorta; aortic valve+ascending aorta) and (ii) at least one of the following additional risk factors: (a) a high perioperative risk profile, defined as predicted operative mortality of ≥8% (EuroSCORE II), (b) age ≥70, (c) Clinical Frailty Score 4 or more, (d) urgent surgery (defined as to be performed within 24-48 hours after admission), (e) left ventricular ejection fraction \\\u003C35%\n\nExclusion Criteria:\n\n1. Known hypersensitivity to fish oil\u002Ffish products or egg protein\n2. Pregnancy or lactation period\n3. Previous history of chronic atrial fibrillation, atrial flutter and\u002For atrial tachyarrhythmia\n4. Inability or unwillingness of individual to give written informed consent\n5. Not expected to survive an additional 48 hours from screening evaluation\n6. Lack of commitment to full, aggressive care (anticipated withholding or withdrawing treatments in the first week but isolated \"Do not Resuscitate\" \\[DNR\\] acceptable)\n7. Patients admitted with diabetic ketoacidosis or non-ketotic hyperosmolar coma\n8. Patients receiving extracorporeal mechanical assist device (e.g. ECLS, or IABP) or advanced heart failure therapies (e.g. TAH, VAD)\n9. Enrolment in anyinterventional trial within the last 30 days\n10. Already receiving FO-containing medical nutrition products\n11. Severe malnutrition (as defined by the BMI \\\u003C18.5)\n12. Severe liver dysfunction defined by Child Pugh Class C.\n13. Severe chronic kidney dysfunction defined by the National Kidney Foundation (NKF) stage 4 and 5 by using the glomerular filtration rate (GFR \\\u003C30ml\u002Fmin)\n14. Known severe coagulation disorder","ALL","18 Years",{"count":20,"type":21},550,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","The MODIFY CSX study is a prospective, randomized, placebo-controlled trial conducted in heart centers in Germany and Italy.\n\nA total of 550 high-risk cardiac surgery patients will receive either 0.20 g fish oil\u002Fkg body weight (BW) + standard of care versus same volume of placebo (NaCl) + standard of care.",[27,28,29,30,31,32,33,34,35,36,37,38],"Intensive Care Unit","Coronary Artery Bypass Grafting (CABG)","High Risk Patients","Cardiopulmonary Bypass","Elective Cardiac Surgery","Valvular Heart Surgery","Multiple Valve Surgeries","Combined Cardiac Procedures","Aortic Surgical Procedures","Adult Patients ≥ 18 Years","Combined Valve and CABG","Combined Cardiac and Aortic Surgical Procedures",[40,41,42,43,44,45,46],"intensive care unit","elective cardiac surgery","fish oil","medical nutrition therapy","atrial fibrillation","atrial flutter","atrial tachycardia","RECRUITING","2026-02-19",{"date":50,"type":51},"2026-02-23","ACTUAL",{"date":53,"type":51},"2024-02-15",{"date":55,"type":21},"2030-09",{"name":57,"class":58},"GCP-Service International West GmbH","INDUSTRY",10,{"id":61,"slug":62,"hasResults":11,"nctId":63,"briefTitle":64,"officialTitle":65,"acronym":66,"eligibilityCriteria":67,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":68,"targetDuration":4,"studyType":22,"phases":70,"briefSummary":72,"conditions":73,"keywords":74,"overallStatus":78,"whyStopped":4,"lastUpdateSubmitDate":79,"lastUpdatePostDateStruct":80,"startDateStruct":82,"completionDateStruct":84,"leadSponsor":86,"locationsCount":4},"100621940","improving-the-quality-of-coronary-artery-bypass-grafting-100621940","NCT07377149","Improving the Quality of Coronary Artery Bypass Grafting","Quality Improvement Intervention on Utilization of Arterial Grafts for Coronary Artery Bypass Grafting","CABG Quality","Patients whose data used to monitor the quality\n\nInclusion Criteria:\n\nAged ≥ 18 years old； Indicated for CABG and undergoing CABG.\n\nExclusion Criteria:\n\nHistory of prior CABG; Concurrent other cardiac surgeries on the day of CABG; Malignant tumor or life expectancy \\\u003C 1 year;\n\n* 50% stenosis of left subclavian artery; Pregnant women; Individuals diagnosed with mental illness or cognitive impairment (International Classification of Diseases-10 codes F01-F99); Patients considered by the investigator to have other factors unsuitable for inclusion.",{"count":69,"type":21},8700,[71],"NA","This is a healthcare quality improvement study focused on increasing the utilization of arterial grafts in isolated coronary artery bypass grafting (CABG). Evidence indicates that arterial grafts, compared with venous grafts, provide superior long-term patency, which are recommended to use by the clinical practice guidelines.\n\nIn hospitals where the use of the internal mammary artery as a graft is relatively low(\\\u003C90%) among CABG patients, multiple interventions will be implemented to improve its adoption rate.\n\nIn hospitals where internal mammary artery graft utilization is already high(≥90%), various interventions will be introduced to promote the use of multiple arterial grafts (defined as the use of two or more arterial conduits).\n\nThe study targets healthcare professionals as the primary subjects of intervention, with no direct interventions applied to patients during the study period. Changes in the internal mammary artery graft utilization rate and the multiple arterial graft utilization rate before and after the intervention will serve as the primary endpoints for evaluating intervention effectiveness in the two types of hospitals, respectively.",[28],[75,76,77],"coronary artery bypass grafting","quality improvement","arterial graft","NOT_YET_RECRUITING","2026-01-22",{"date":81,"type":51},"2026-01-29",{"date":83,"type":21},"2026-03-15",{"date":85,"type":21},"2029-07",{"name":87,"class":88},"China National Center for Cardiovascular Diseases","OTHER_GOV",{"id":90,"slug":91,"hasResults":11,"nctId":92,"briefTitle":93,"officialTitle":94,"acronym":4,"eligibilityCriteria":95,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":96,"enrollmentInfo":97,"targetDuration":4,"studyType":22,"phases":99,"briefSummary":101,"conditions":102,"keywords":4,"overallStatus":47,"whyStopped":4,"lastUpdateSubmitDate":105,"lastUpdatePostDateStruct":106,"startDateStruct":108,"completionDateStruct":110,"leadSponsor":112,"locationsCount":5},"100613343","phase-1-a-phase-iii-clinical-trial-of-intramyocardial-injection-of-hucmscs-for-the-treatment-of-chronic-heart-failure-100613343","NCT07265349","A Phase I\u002FII Clinical Trial of Intramyocardial Injection of HucMSCs for the Treatment of Chronic Heart Failure","A Phase I\u002FII Clinical Trial to Evaluate the Safety and Efficacy of Intramyocardial Injection of Human Umbilical Cord Mesenchymal Stem Cells (HucMSCs) Combined With Coronary Artery Bypass Grafting in the Treatment of Chronic Heart Failure Caused by Chronic Ischemic Cardiomyopathy","Inclusion Criteria:\n\n* 1\\) Age from 18 to 80 years, both genders are eligible ;\n* 2\\) Clinically judged to be suitable for CABG treatment due to chronic ischemic cardiomyopathy;\n* 3\\) LVEF (left ventricular ejection fraction) is ≤ 40% as indicated by echocardiography (modified Simpson method) or cardiac magnetic resonance (CMR);\n* 4\\) NYHA (New York Heart Association) cardiac function classification of grade II-IV;\n* 5\\) Patients or their legal guardians agreed to participate in this trial and signed the informed consent form.\n\nMajor exclusion Criteria:\n\n* 1\\) Severe left ventricular dysfunction, with LVEF ≤ 20% (based on the UCG or CMR examination results during the screening period);\n* 2\\) Non-ischemic chronic left heart dysfunction, including but not limited to acute left heart dysfunction, dilated cardiomyopathy, severe right heart dysfunction (such as bilateral lower extremity edema accompanied by jugular vein distension, liver enlargement, etc.) or severe pulmonary hypertension (PASP \\> 70 mmHg);\n* 3\\) Clinically determined that other surgical procedures need to be performed simultaneously during CABG surgery, including but not limited to congenital heart disease requiring concurrent surgical intervention, heart valve disease, ventricular aneurysm, ventricular septal perforation, papillary muscle dysfunction, aortic dissection, intracardiac mass, thrombus or neoplasm；\n* 4\\) Acute ST-segment elevation myocardial infarction or stroke event within 1 month before enrollment；\n* 5\\) Uncontrolled malignant arrhythmia;\n* 6)have undergone or are awaiting heart transplantation or implantation of a left ventricular assist device (LVAD).","80 Years",{"count":98,"type":21},51,[100,24],"PHASE1","B2278 is a human umbilical cord mesenchymal stem cell (HucMSCs) injection derived from the umbilical cord. It has the advantages of stronger immune regulation, stronger expansion capacity, lower immunogenicity, and greater accessibility. The preliminary research results indicated that the B2278 injection promote the polarization of macrophages towards a reparative state through paracrine action, directly promote angiogenesis and inhibited inflammatory responses, thereby exerting effects on myocardial repair and treatment of heart failure, and it is also safe and well-tolerated.\n\nThis trial is a multi-center I\u002FII phase clinical trial of the human umbilical cord mesenchymal stem cell injection solution, aiming to explore the dosage and regimen for the intramyocardial injection of B2278 in combination with coronary artery bypass grafting surgery for the treatment of chronic heart failure caused by chronic ischemic cardiomyopathy, and to evaluate the safety, tolerance and efficacy of allogeneic intramyocardial injection of the human umbilical cord mesenchymal stem cell injection solution in patients with chronic ischemic heart failure.",[28,103,104],"Chronic Heart Failure","Chronic Ischemic Cardiomyopathy","2026-01-07",{"date":107,"type":51},"2026-01-09",{"date":109,"type":51},"2025-12-26",{"date":111,"type":21},"2027-08-01",{"name":113,"class":58},"Tasly Pharmaceutical Group Co., Ltd",{"id":115,"slug":116,"hasResults":11,"nctId":117,"briefTitle":118,"officialTitle":119,"acronym":4,"eligibilityCriteria":120,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":121,"targetDuration":4,"studyType":22,"phases":123,"briefSummary":124,"conditions":125,"keywords":4,"overallStatus":47,"whyStopped":4,"lastUpdateSubmitDate":127,"lastUpdatePostDateStruct":128,"startDateStruct":130,"completionDateStruct":132,"leadSponsor":134,"locationsCount":137},"100561176","effect-of-nurse-led-education-and-tele-interventions-on-reducing-surgical-site-infections-in-patients-after-coronary-artery-bypass-surgery-a-clinical-trial-100561176","NCT06586749","Effect of Nurse-Led Education and Tele-Interventions on Reducing Surgical Site Infections in Patients After Coronary Artery Bypass Surgery: a Clinical Trial","The Effect of Patient Education and Implementation of Teleinterventions by Nurses, on the Incidence of Surgical Wound Infections, in Patients After Coronary Artery Bypass Surgery","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Patients who have undergone CABG with median sternotomy\n* Proficiency in reading and writing in Greek\n* Patients who provide written informed consent for participation in the study\n* Patients who have access to a mobile phone and know how to use it\n* Patients without difficulties in vision, speech, or hearing\n* Patients at intermediate or high risk for developing surgical site infections, based on their scores in the risk stratification models described below\n\nExclusion Criteria:\n\n* History of psychiatric illness, recent history of alcohol and\u002For substance abuse, dementia, and Alzheimer's disease\n* Presence of an active infection within 2 weeks prior to the surgical procedure\n* Preoperative hospitalization \\> 2 days\n* Concurrent surgery on the aorta or heart valves\n* Urgent or emergency nature of the surgical procedure\n* Re-sternotomy aimed at surgical re-exploration of bleeding or implementation of cardiopulmonary resuscitation (CPR) in cases of cardiac arrest\n* Patients in whom the sternum has not been closed after the completion of the surgical procedure and who are transferred to the cardiothoracic unit without sternum closure\n* Active endocarditis\n* Life expectancy \\\u003C 6 months\n* Lack of a smartphone",{"count":122,"type":21},220,[71],"The goal of this clinical trial is to determine if nurse-led education and tele-interventions can reduce the incidence of surgical wound infections in patients after coronary artery bypass surgery. The main questions it aims to answer are:\n\n* Can nurse-led education reduce the rate of surgical wound infections after coronary artery bypass surgery?\n* Does the addition of tele-interventions further decrease the incidence of these infections compared to standard care?\n\nResearchers will compare three groups:\n\n* Group A: Standard postoperative care\n* Group B: Nurse-led patient education\n* Group C: Nurse-led patient education plus tele-interventions\n\nParticipants will:\n\n* Receive standard care, nurse-led education, or nurse-led education with tele-interventions\n* Having regular follow-up as per group assignment\n* Monitor and report infection during the study period",[126,28],"Surgical Site Infection","2024-09-04",{"date":129,"type":51},"2024-09-19",{"date":131,"type":51},"2024-03-01",{"date":133,"type":21},"2025-09-01",{"name":135,"class":136},"Hellenic Mediterranean University","OTHER",1]